Identification of Genes Expressed in Atherosclerotic Plaque

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

69 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-10-21

Study Completion Date

2011-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will identify genes and proteins in the blood of patients with atherosclerosis and in that of normal volunteers. The findings will be compared to determine the influence of these substances on the development of atherosclerosis a narrowing and hardening of blood vessel walls by deposits of fatty substances. Blood vessel blockage caused by atherosclerosis can impede blood flow and cause stroke, heart attack and poor limb circulation. The information from this study may lead to better ways to detect, prevent and treat these diseases.

Healthy volunteers and patients scheduled for carotid endarterectomy at Suburban Hospital in Bethesda, Maryland, are eligible for this study. Carotid endarterectomy is a surgical procedure in which the inner layer of the carotid artery (neck artery supplying blood to the brain) is scraped away to open the blocked vessel. Participants will undergo the following tests and procedures:

Patients

* Blood sample: Collection of about 32 cc (8 tablespoons) of blood for genetic and protein analysis
* Tissue sample: Collection of a piece of diseased blood vessel discarded from the endarterectomy procedure
* Review of records: Review of medical records for information about past illnesses, medications, tests, and so forth, if needed

Normal Volunteers

* Blood samples: Collection of about 32 cc (8 tablespoons) of blood for genetic and protein analysis
* Carotid artery ultrasound: Ultrasound imaging of the neck arteries for detection of any blockage
* Electrocardiogram: Recording of the electrical activity of the heart to detect any abnormalities in heart rhythm
* Echocardiogram: Ultrasound examination to detect possible abnormalities of the heart muscle
* Cardiac stress test: Treadmill stress test to detect possible heart vessel blockage (for subjects who have not had a cardiac stress test in the past year)
* Review of records: Review of medical records for information about past illnesses, medications, tests, and so forth, if needed

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Genes Predisposing to Atherosclerosis

NCT00059098

Cardiovascular Diseases Coronary Disease Heart Diseases

COMPLETED

Genetic Factors in Atherosclerosis

NCT00359307

Atherosclerosis

COMPLETED

Understanding the Genetic Basis of Atherosclerosis and Peripheral Arterial Disease

NCT00380185

Peripheral Vascular Diseases

COMPLETED

Understanding the Genetic and Hereditary Basis of Atherosclerosis

NCT00344292

Atherosclerosis Cardiovascular Diseases

COMPLETED

Inflammatory Genomics in Human Carotid Artery Disease

NCT00070668

Cardiovascular Diseases Atherosclerosis Carotid Artery Diseases +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Significant progress has been made in the prevention and treatment of atherosclerosis, but it continues to be a leading cause of morbidity and mortality in our society. The problem will become even more significant as an increasing proportion of the population ages. The goal of the proposed project is to advance our understanding of the genetic mechanisms of atherosclerosis. We propose to identify genes selectively expressed in peripheral monocytes of patients with atherosclerosis and in macrophages and endothelial cells of atherosclerotic plaques. We will examine gene expression profiles in purified subpopulations of cells using Serial Analysis of Gene Expression (SAGE) that requires only minute amounts of RNA, enabling the study of small homogeneous populations of cells. This sequence-based high-throughput gene expression profiling technique has the advantage of not requiring prior knowledge of the expressed gene sequences, allowing the discovery of new genes. With the completion of the human genome sequence, the SAGE technique is an ideal tool for comprehensively characterizing the transcriptomes of the important cells involved in atherosclerosis. This proposal is an exploratory study to find candidates, both known and unknown genes, which will be used for more extensive and statistically powered projects in the future. The insights obtained will be used for elucidating the pathogenesis of atherosclerosis and for developing new simple, sensitive and specific tests for early disease diagnosis. In addition, the new insights obtained may lead to the development of novel therapeutic strategies for disease prevention and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Any adult patient with carotid artery disease or known atherosclerosis capable of giving informed consent.

Any adult with normal total cholesterol (less than 200 mg/dl) and blood pressure (systolic less than 140 and diastolic less than 90).

Any healthy adult subject with no history of peripheral or coronary artery disease, who is eligible for bronchoalveolar lavage per Protocol 99-H-0068 and capable of giving informed consent.

Exclusion Criteria

Unable to give consent

History of chronic infections, vasculitis or any other inflammatory disease

History of neoplastic disease or chemotherapy treatment

Immunosuppressive medications other than common over-the-counter drugs such as aspirin or acetaminophen

Subject with abnormal liver and renal function tests on pretreatment screening or currently taking a statin or ACE inhibitor medication.

Minimum Eligible Age

21 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No